Potassium 1-methyl-1H-pyrazole-5-trifluoroborate
Product Information
Molecular Formula
C4H5BF3KN2
Molecular Weight
188.00
Description
Potassium 1-methyl-1H-pyrazole-5-trifluoroborate is a widely employed compound in the biomedical industry. Prominently utilized in pharmaceutical drug development, particularly for diverse disease treatments, this compound's exceptional properties enable its integration into targeted drug formulations.
Synonyms
Potassium trifluoro(1-methyl-1H-pyrazol-5-yl)borate
IUPAC Name
potassiumtrifluoro-(2-methylpyrazol-3-yl)boranuide
SMILES
[B-](C1=CC=NN1C)(F)(F)F.[K+]
InChI
InChI=1S/C4H5BF3N2.K/c1-10-4(2-3-9-10)5(6,7)8/h2-3H,1H3/q-1+1
InChI Key
UJQYAMWDUIKNDK-UHFFFAOYSA-N
Melting Point
230-275 °C
Purity
95%
Safety Information
Hazards
H302-H315-H319-H335
Precautionary Statement
P261-P305 + P351 + P338
Computed Properties
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
5
Rotatable Bond Count
0
Exact Mass
188.0134943 g/mol
Monoisotopic Mass
188.0134943 g/mol
Topological Polar Surface Area
17.8Ų
Heavy Atom Count
11
Formal Charge
0
Complexity
131
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
2
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| AU-2015268962-A1 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | 2014-06-04 |
| EP-3151833-A1 | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions | 2014-06-04 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | 2014-06-04 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | 2014-06-04 |
| US-2017196873-A1 | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions | 2014-06-04 |
| US-2019000856-A1 | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions | 2014-06-04 |
| WO-2015187089-A1 | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions | 2014-06-04 |
